What the research shows
Two randomized trials asked people with EPP to record time in direct sunlight without pain. In the U.S. study, the median over six months was 69.4 hours with the afamelanotide implant and 40.8 with placebo. That comparison concerns pain-free exposure in people with EPP. The investigators did not evaluate cosmetic tanning in the general population. Read the randomized trials.
The U.S. prescribing information describes the indicated patient population and the implant’s construction. Read the Scenesse label.
Documented formats
Scenesse is a solid, bioresorbable rod. Its polymer and peptide together form the implant evaluated in the trials.
Testing and purity
Check the product name, active ingredient and implant description together. A sequence match alone tells you little about how a finished implant releases its contents.
How to read a batch reportQuestions about Melanotan I
Was 69.4 hours one period outdoors?
It was the median accumulated time in pain-free direct sunlight over the six-month U.S. study.
Does Melanotan II identify the same ingredient?
Melanotan II is a different, shorter cyclic peptide. The Scenesse label identifies afamelanotide as its active ingredient.